TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00988507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT04266626

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral motor manipulation therapy
Description: Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
Study: NCT00988507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT00846755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine, Propylthiouracile
Description: Drugs were titrated to render euthyroid pregnant patients with thyroid disease
Study: NCT01948557

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Infant feeding counselling and support
Description: Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice.
Study: NCT01532609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMT CARE
Description: Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
Study: NCT01753440

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).
Description: Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
Study: NCT03367416

Intervention type: BEHAVIORAL
Intervention: NIATx model
Description: The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~1. educating executives on how to promote effective process change techniques~2. training staff teams in the theory and practice of organizational change techniques~3. training staff to develop and implement a process improvement intervention~4. implementing a sustainability plan to institutionalize change and avoid reverting to previous methods
Study: NCT00813709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
Study: NCT04249700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curve Sauna Dome
Description: All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
Study: NCT03022825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 and BCG
Description: BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
Study: NCT04577391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy
Description: Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bimanual Training
Description: BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
Study: NCT03152214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous Intensity Aerobic Exercise and Community Engagement
Description: Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at \> 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Engagement
Description: Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
Study: NCT02672592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra 100mg s.c. bid
Study: NCT01721694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin 1.5%/Loteprednol 0,5% + placebo
Description: 1 drop, AO, QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin 1.5% + Loteprednol 0,5% (separately)
Description: 1 drop, QID, AO
Study: NCT03240029

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
Study: NCT00451178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
Study: NCT02400528

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: quality of life questionnaires
Study: NCT00624377

Intervention type: DRUG
Intervention: Tiotropium
Description: Tiotropium 18 mcg HandiHaler once daily
Study: NCT02443012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Gutt Nepafenac 0.1%
Description: Topical Nepafenac as an adjunct to focal/grid laser

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser
Description: Grid/Focal Laser Photocoagulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Grid/Focal Laser Photocoagulation
Study: NCT04885660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: compound lisinopril tablet(Lisonorm®)
Description: The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
Study: NCT00630760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX 194204
Description: NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
Study: NCT00958399

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: 25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch + soluble fiber
Description: 25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber made from corn starch
Description: 25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber made from corn starch + soluble fiber
Description: 25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
Study: NCT04244227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empower Neuromodulation System
Description: Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
Study: NCT04867772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: Home based rehabilitation
Study: NCT03883724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral treatment of insomnia (BBTI)
Description: The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information-only control (IC)
Description: The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
Study: NCT03779945

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous platelet rich plasma
Description: adding autologous platelet rich plasma to the bone graft harvested from the patient
Study: NCT04244227

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Empower Neuromodulation System
Description: Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
Study: NCT00630942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg capsules twice a day before breakfast and before dinner.
Study: NCT04306627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment
Description: comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment
Description: comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
Study: NCT04517825

Intervention type: DIAGNOSTIC_TEST
Intervention: Cepheid Xpert HIV-1 Viral Load Assay
Description: Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
Study: NCT02549040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Doravirine 100 mg film coated tablet
Description: Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
Study: NCT02672592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9% s.c. bid
Study: NCT00451178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study: NCT04185506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT+BWL
Description: DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
Study: NCT03492931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients will receive a single dose of ticagrelor
Study: NCT02549040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)
Description: Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)
Description: Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)
Description: Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)
Description: Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
Study: NCT01337440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.
Study: NCT03726099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole, amoxicillin, furazolidone，tetracycline
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
Study: NCT04274972

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome evaluation
Description: The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
Study: NCT01897779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX2014
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination RPX7009 and RPX2014
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Study: NCT02172820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Patients in the experimental group will receive financial incentives for completing exercise sessions.
Study: NCT03779945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posteriolateral lumbar fusion only
Description: performing posteriolateral lumbar fusion without using platelet rich plasma
Study: NCT03936725

Intervention type: OTHER
Intervention: 1 year phone call : data collection
Description: Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up.
Study: NCT04514094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF
Description: SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.